Agenus reports response rate in colon cancer trial (AGEN:NASDAQ)

Agenus reports response rate in colon cancer trial (AGEN:NASDAQ)

Agenus colon cancer trial showed 72% complete responses before surgery.

Genmab Announces Updated Follow-Up Analyses from Phase 2 Study of Petosemtamab Demonstrate Meaningful Objective Response Rates in Patients with Metastatic Colorectal Cancer - PressReach

Media Release COPENHAGEN, Denmark; October 25, 2026 Petosemtamab demonstrates encouraging objective response rates (ORRs), with promising depth and durability of response, in first- and second-line metastatic colorectal cancer (mCRC) Data reinforces the ongoing global Phase 3 trials of petosemtamab in mCRC, which are actively enrolling patients Genmab A/S (Nasdaq: GMAB) today announced updated follow-up analyses … Continue reading "Genmab Announ…

Agenus Reports 72% Pathologic Complete Response in dMMR Colon Cancer Cohort

The 18-patient Phase 2 cohort also met the study’s primary major pathologic response measure in 83% of patients.

Genmab reports 75% response in colorectal cancer study

Genmab reports 75 per cent first-line response with petosemtamab and chemotherapy; uncontrolled Phase 2 findings include unconfirmed responses.

Genmab Announces Updated Follow-Up Analyses from Phase 2 Study of Petosemtamab Demonstrate Meaningful Objective Response Rates in Patients with Metastatic Colorectal Cancer